- Direction
- Improving
- Own history
- 80th
- Peers
- 83th
- Persistence
- EMERGING
· Special Industry Machinery, NEC
RESEARCH SNAPSHOTAzenta, Inc.'s latest supported as-filed period reports revenue of $161.2M; gross margin moved 218 basis points lower on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 4.12% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 0.90% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 11.97% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 49.06% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 44.89% · CORE
Level · gp.fundamentals.operating_margin
Raw value -2.59% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 29.8%; Operating cash flow decreased 94.4%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 12.0%; Operating margin moved 210 bp lower; Operating income decreased 485.2%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Gross margin moved 218 bp lower; Operating margin moved 210 bp lower.
2 evidence-backed componentsOperating cash flow changed -94.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
AZTA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-062354SEC ↗4Sep 16, 2026Period Sep 14, 20260001628280-26-062348SEC ↗4Sep 16, 2026Period Sep 14, 20260001628280-26-062345SEC ↗4Sep 16, 2026Period Sep 14, 20260001628280-26-062344SEC ↗4Sep 16, 2026Period Sep 14, 20260001628280-26-062343SEC ↗4Sep 16, 2026Period Sep 15, 20260001628280-26-062341SEC ↗8-KSep 4, 2026Period Sep 3, 20260001628280-26-060614SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 15, 2026Filed Sep 16, 2026 | Bello Erik J.VP Chief Accounting Officer | Grant Or AwardDirect | 4,586 | $0 | $0 | Form 4 ↗ |
| Sep 14, 2026Filed Sep 16, 2026 | Pirogova OlgaSVP and CHRO | Grant Or AwardDirect | 15,272 | $0 | $0 | Form 4 ↗ |
| Sep 14, 2026Filed Sep 16, 2026 | Madaus Martin DInterim CEO | Grant Or AwardDirect | 36,653 | $0 | $0 | Form 4 ↗ |
| Sep 14, 2026Filed Sep 16, 2026 | MARTIN WILLIAM E. IIIPresident Multiomics | Grant Or AwardDirect | 15,272 | $0 | $0 | Form 4 ↗ |
| Sep 14, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 5.49% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 2.91% · OPTIONAL
Operating income changed -485.2% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating margin changed -210 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Gross margin changed -218 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Cash & equivalents changed -29.8% from the comparable as-filed period.
Capex / revenue changed -341 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Research & development changed +32.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-058519| Lin Lawrence Y.EVP, CFO and Treasurer |
| Grant Or AwardDirect |
| 30,544 |
| $0 |
| $0 |
| Form 4 ↗ |
| Sep 14, 2026Filed Sep 16, 2026 | Starr EphraimSVP, Gen Counsel & Secretary | Grant Or AwardDirect | 15,272 | $0 | $0 | Form 4 ↗ |
| Aug 9, 2026Filed Aug 11, 2026 | Pirogova OlgaSVP and CHRO | Tax WithholdingDirect | 1,085 | $32 | $34,763 | Form 4 ↗ |
| Jul 31, 2026Filed Aug 4, 2026 | Starr EphraimSVP, Gen Counsel & Secretary | Open Market PurchaseDirect | 335 | $24 | $8,096 | Form 4 ↗ |
| May 18, 2026Filed May 19, 2026 | Cornog William LDirector | Open Market PurchaseIndirect | 10,000 | $16 | $163,800 | Form 4 ↗ |
| May 15, 2026Filed May 18, 2026 | Starr EphraimSVP, Gen Counsel & Secretary | Tax WithholdingDirect | 3,621 | $16 | $58,008 | Form 4 ↗ |
| Apr 28, 2026Filed Apr 30, 2026 | MARTIN WILLIAM E. IIIPresident Multiomics | Grant Or AwardDirect | 17,790 | $24 | $431,230 | Form 4 ↗ |
| Feb 6, 2026Filed Feb 6, 2026 | Nova Tina SusanDirector | Grant Or AwardDirect | 5,663 | $28 | $157,715 | Form 4 ↗ |
| Feb 5, 2026Filed May 12, 2026 | Koffey QuentinDirector | Grant Or AwardDirect | 5,663 | $0 | $0 | Form 4 ↗ |
| Feb 5, 2026Filed Feb 6, 2026 | Cornog William LDirector | Grant Or AwardDirect | 5,663 | — | — | Form 4 ↗ |
| Feb 5, 2026Filed Feb 6, 2026 | Casal FrankDirector | Grant Or AwardDirect | 7,243 | $28 | $201,718 | Form 4 ↗ |
| Feb 5, 2026Filed Feb 6, 2026 | Doshi DipalDirector | Grant Or AwardDirect | 5,663 | $28 | $157,715 | Form 4 ↗ |
| Feb 5, 2026Filed Feb 6, 2026 | Madaus Martin DDirector | Grant Or AwardDirect | 5,663 | — | — | Form 4 ↗ |